Table 2.
DI-MS/MS based on 20 important metabolites (VIP > 1.0) that contributed to separate 90-day non-survivors from survivors
| Quantified metabolites by DI-MS/MS | ||
|---|---|---|
| Increased in non-survivors | Decreased in non-survivors | |
| 1 | C5-DC (C6-OH) (glutaryl-l-carnitine) | Tryptophan |
| 2 | C3-DC (C4-OH) (malonyl carnitine) | LysoPC a C18:0 |
| 3 | C5-M-DC (methylglutaryl-l-carnitine) | LysoPC a C18:1 |
| 4 | C5:1 (tigyl-l-carnitine) | PC aa C38:5 |
| 5 | Glycine | PC aa C38:4 |
| 6 | C9 (lysophophatidylethanolamine, nonayl-l-carnitine) | LysoPC a C16:1 |
| 7 | PC ae C40:2 (glycerol 3-phosphocholine) | |
| 8 | PC aa C42:1 (lecithin, PC) | |
| 9 | PC aa C40:3 | |
| 10 | PC ae C36:1 | |
| 11 | PC ae C38:1 (lecithin, phosphatidylcholine) | |
| 12 | PC aa C40:1 (lecithin, PC) | |
| 13 | PC aa C42:2 (lecithin, PC) | |
| 14 | PC aa C40:2 | |
This shows the increased and decreased metabolites in non-survivors vs. survivors. The order of metabolites reflects the relative amount of change